Cirrhosis

/Tag:Cirrhosis

Abstract Number: 1079

NOT YOUR TYPICAL ANGINA

Case Presentation: A 67 year-old-man with a history of hepatitis C cirrhosis and a recent diagnosis of hepatocellular carcinoma (HCC) presented with six months of worsening dyspnea on exertion and one month of progressive typical [...]

By | 2019-03-11T14:44:54+00:00 March 11th, 2019|Adult, Clinical Vignettes, Hospital Medicine 2019|Comments Off on NOT YOUR TYPICAL ANGINA

Abstract Number: 1076

PREVENTABLE PERIL OF PARACENTESIS: INCARCERATED UMBILICAL HERNIA

Case Presentation: A 34-year-old man with decompensated cirrhosis secondary to chronic hepatitis C (MELD 21) presented with a chief complaint of severe abdominal pain. He routinely received outpatient paracentesis weekly, which was last performed 4days [...]

By | 2019-03-11T14:44:51+00:00 March 11th, 2019|Adult, Clinical Vignettes, Hospital Medicine 2019|Comments Off on PREVENTABLE PERIL OF PARACENTESIS: INCARCERATED UMBILICAL HERNIA

Abstract Number: 622

IT’S NOT JUST A TEST QUESTION: VIBRIO VULNIFICUS NECROTIZING MYOFASCIITES

Case Presentation: A 51- year old male with a past medical history of cirrhosis due to sarcoidosis, was admitted with worsening left lower extremity pain and swelling for two days. He remembered a pop in [...]

By | 2019-03-11T14:31:20+00:00 March 11th, 2019|Adult, Clinical Vignettes, Hospital Medicine 2019|Comments Off on IT’S NOT JUST A TEST QUESTION: VIBRIO VULNIFICUS NECROTIZING MYOFASCIITES

Abstract Number: 395

RIFAXIMIN AND LACTULOSE COMBINATION THERAPY VERSUS LACTULOSE ALONE FOR PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE: A POOLED ANALYSIS OF TWO RANDOMIZED TRIALS

Background: Rifaximin 550 mg tablets is a nonsystemic antibiotic indicated for reducing the risk of overt hepatic encephalopathy (HE) recurrence in adults and may be used in combination with lactulose. Practice guidelines state that rifaximin [...]

By | 2019-03-11T14:25:21+00:00 March 11th, 2019|Hospital Medicine 2019, Research, Transitions of Care|Comments Off on RIFAXIMIN AND LACTULOSE COMBINATION THERAPY VERSUS LACTULOSE ALONE FOR PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE: A POOLED ANALYSIS OF TWO RANDOMIZED TRIALS

HM2018 Abstract Number: 331

PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE WITH RIFAXIMIN ALONE VERSUS RIFAXIMIN PLUS LACTULOSE THERAPY: IMPACT ON QUALITY OF LIFE AND CAREGIVER BURDEN IN PATIENTS WITH CIRRHOSIS

Background: Rifaximin, a nonsystemic antibiotic, may be used alone or in combination with lactulose for reducing the risk of overt hepatic encephalopathy (OHE) recurrence in adults. This analysis evaluated rifaximin alone and rifaximin + lactulose [...]

By | 2018-03-19T15:44:00+00:00 March 19th, 2018|Research, Transitions of Care, Uncategorized|Comments Off on PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE WITH RIFAXIMIN ALONE VERSUS RIFAXIMIN PLUS LACTULOSE THERAPY: IMPACT ON QUALITY OF LIFE AND CAREGIVER BURDEN IN PATIENTS WITH CIRRHOSIS

HM2018 Abstract Number: 361

TEMPORAL TREND OF HOSPITALIZATION AND MORTALITY ASSOCIATED WITH LIFE-THREATENING COMPLICATION OF CIRRHOSIS

Background: The number of hospitalizations related to a primary diagnosis of cirrhosis has been declining since the mid-2000’s. However, the temporal trend of number of hospitalizations and inpatient mortality associated with secondary conditions of cirrhosis [...]

By | 2018-03-19T13:06:42+00:00 March 19th, 2018|Hospital Medicine 2018, Research, Value in Hospital Medicine|Comments Off on TEMPORAL TREND OF HOSPITALIZATION AND MORTALITY ASSOCIATED WITH LIFE-THREATENING COMPLICATION OF CIRRHOSIS

HM2018 Abstract Number: 560

A SHOCKING CASE OF DECOMPENSATED CIRRHOSIS: THE HEPATO-ADRENAL SYNDROME

Case Presentation: A 46 year-old man with decompensated cirrhosis (MELD 45) presented with dizziness and confusion for two days. He denied any other new symptoms. Home medications included lactulose, propranolol, pantoprazole, folic acid and thiamine. [...]

By | 2018-03-19T12:55:04+00:00 March 19th, 2018|Adult, Clinical Vignettes, Hospital Medicine 2018|Comments Off on A SHOCKING CASE OF DECOMPENSATED CIRRHOSIS: THE HEPATO-ADRENAL SYNDROME

HM2018 Abstract Number: 359

ECONOMIC BURDEN OF OVERT HEPATIC ENCEPHALOPATHY AND PHARMACOECONOMIC IMPACT OF RIFAXIMIN

Background: Hepatic encephalopathy (HE) is a common neurological complication in patients with cirrhosis. In addition to numerous morbidity-related issues, HE is associated with substantial economic burden. Treatment includes lactulose or rifaximin, a nonsystemic antibiotic that [...]

By | 2018-03-19T12:52:34+00:00 March 19th, 2018|Hospital Medicine 2018, Research, Value in Hospital Medicine|Comments Off on ECONOMIC BURDEN OF OVERT HEPATIC ENCEPHALOPATHY AND PHARMACOECONOMIC IMPACT OF RIFAXIMIN

HM2016 Abstract Number: 204

Characterizing the Safety of Paracentesis in Hospitalized Patients with Cirrhosis and Ascites from 2004-2012 in the United States

Background: Paracentesis is associated with decreased mortality in patients with advanced liver disease. The prevalence of paracentesis related complications is not well characterized, but prior studies suggest improved safety outcomes when ultrasound guidance is employed.  [...]

By | 2016-02-01T08:00:34+00:00 February 1st, 2016|Quality Improvement, Research Abstracts|Comments Off on Characterizing the Safety of Paracentesis in Hospitalized Patients with Cirrhosis and Ascites from 2004-2012 in the United States

HM2016 Abstract Number: 76

Liver Imaging After Successful Treatment in Hcv-Infected Patients with Cirrhosis

Background: Patients with cirrhosis and hepatitis C virus (HCV) infection who have achieved sustained virologic response (SVR) currently undergo indefinite imaging every 6-12 months to screen for hepatocellular carcinoma (HCC). Although current research shows there [...]

By | 2016-02-01T08:00:34+00:00 February 1st, 2016|Other, Research Abstracts|Comments Off on Liver Imaging After Successful Treatment in Hcv-Infected Patients with Cirrhosis